<DOC>
	<DOCNO>NCT01002235</DOCNO>
	<brief_summary>The purpose study assess safety tolerability inject VM202 leg muscle patient painful diabetic neuropathy ( DPN ) . The study also assess potential VM202 reduce pain associate DPN .</brief_summary>
	<brief_title>Gene Therapy Painful Diabetic Neuropathy</brief_title>
	<detailed_description>Peripheral neuropathy serious complication diabetes . This form neuropathy carry high risk pain , trophic change autonomic dysfunction . Currently , approve drug interventional strategy know halt reverse progression DPN . Treatments target pain reduction , physical function improvement , reduction psychological distress , quality life improvement . There currently effective treatment diabetic neuropathy , good glycemic control way minimize risk occurrence . Clearly , would desirable prevent , impede , reverse disrupt often life-threatening manifestation peripheral neuropathy stimulate growth regeneration peripheral nerve axon .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Age ≥ 18 year 75 year Documented history Type I II diabetes current treatment control ( glycosylated hemoglobin A1c ≤ 10.0 % ) Diagnosis painful diabetic peripheral neuropathy low extremities The physical examination component Michigan Neuropathy Screening Instrument Score ( MNSI ) ≥ 3 Screening Visual analog scale ( VAS ) score ≥ 4 cm Screening ( 0 cm = pain 10 cm worst imaginable pain ) Stable treatment diabetes least 3 month anticipate change medication regimen , new symptom associate diabetes Lower extremity pain least 6 month If female childbearing potential , negative pregnancy test screen use acceptable method birth control study . Peripheral neuropathy cause condition diabetes ; Other pain severe neuropathic pain ; Progressive degenerative neurological disorder ; Myopathy ; Inflammatory disorder blood vessel ( inflammatory angiopathy , Buerger 's disease ) ; Active infection ; Chronic inflammatory disease ( e.g . Crohn 's , Rheumatoid Arthritis ) Positive HIV HTLV Screening Positive Hepatitis B C determine Hepatitis B core antibody ( HBcAB ) , antibody Hepatitis B antigen ( IgG IgM ; HbsAB ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( AntiHCV ) , Screening know immunosuppression chronic treatment immunosuppressive drug , chemotherapy radiation therapy Stroke myocardial infarction within last 6 month ; Ophthalmologic condition pertinent proliferative retinopathy condition preclude standard ophthalmologic examination : Cataract surgery within 6 month trial ; Vascular lesion anterior segment eye ( infection ulceration cornea , rubeotic glaucoma , etc ) ; Vascular lesion posterior segment eye proliferative retinopathy , macular edema , s/p photocoagulation macular edema proliferative retinopathy ; sickle cell retinopathy , ischemic retinopathy due retinal venous stasis carotid artery disease ; Choroidal angiogenesis ; Large elevate choroidal nevus , choroidal vascular tumor ( choroidal hemangioma ) , melanoma . Specific laboratory value Screening include : Hemoglobin &lt; 9.0 g/dL , WBC &lt; 3,000 cell per microliter , platelet count &lt; 75,000/mm3 , Creatinine &gt; 2.0 mg/dL ; GFR &lt; 50 , AST and/or ALT &gt; 2 time upper limit normal clinically significant lab abnormality opinion investigator exclusionary ; Use gammalinolenic acid ( GLA ) , alpha lipoic acid high dose dietary antioxidant supplement symptomatic relief DPN ; Uncontrolled hypertension define sustain systolic blood pressure ( SBP ) &gt; 200 mmHg diastolic BP ( DBP ) &gt; 110 mmHg baseline/screening evaluation ; Patients history new screen find malignant neoplasm except basal cell carcinoma squamous cell carcinoma skin ( excised evidence recurrence ) ; Malignant tumor abnormal screen test suspicious cancer , patient screen exams indicate possible occult malignancy unless malignancy rule . Patients family history colon cancer first degree relative unless undergone colonoscopy last 12 month negative finding ; Elevated PSA unless prostate cancer exclude ; Subjects require &gt; 81 mg daily acetylsalicylic acid ; If &gt; 81 mg take screening , subject may enrol willing/able switch another medication ; Major psychiatric disorder past 6 month ; History drug alcohol abuse / dependence past 2 year ; History recent tobacco abuse ( within past 5 year ) ; BMI &gt; 38 kg/m2 ; Use investigational drug treatment past 12 month ; Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>peripheral</keyword>
	<keyword>diabetes</keyword>
</DOC>